We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The drugs giant booked revenues of $5.2 billion for the quarter, marking a 4 percent drop from a year ago, or a 9 percent decline at constant exchange rates, while core operating profit plummeted 46 percent (47 percent CER) to $896 million.